Ayala Pharmaceuticals Announces $25 Million Strategic Financing
February 19, 2021 09:29 ET
|
Ayala Pharmaceuticals
Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023 Funds Expected to Support the Recently Announced Accelerated Development of AL102 for the Treatment of Desmoid Tumors...
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer
January 28, 2021 09:15 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor Conference
January 13, 2021 16:01 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect Conference
January 05, 2021 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
January 04, 2021 08:00 ET
|
Ayala Pharmaceuticals
- FDA Agreement from End-of-Phase 1 Meeting to Advance to Potential Registrational Study - - Pivotal Trial Expected to Initiate in 1H21 - REHOVOT, Israel & WILMINGTON, Del., Jan. 04, 2021 ...
Ayala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
November 17, 2020 08:01 ET
|
Ayala Pharmaceuticals
- Presented New Positive Interim Data from 4mg Cohort of Phase 2 ACCURACY Study of AL101 for the Treatment of R/M ACC at European Society for Medical Oncology 2020 - - Trial In Progress Poster of...
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
November 05, 2020 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing...
Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020
September 18, 2020 07:00 ET
|
Ayala Pharmaceuticals
– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate - Company to host virtual KOL event to review data today at 8:00am...
Ayala Pharmaceuticals to Host Virtual KOL Event Reviewing Interim Data Presented at ESMO 2020 from Ongoing Phase 2 ACCURACY Trial of AL101 for the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma
September 14, 2020 08:01 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals to Present at Upcoming Investor Conferences
September 08, 2020 08:01 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small...